The effects of PI3K/Akt/mTOR pathway inhibitors on a panel of NSCLC cell lines

被引：0
|
作者：
Heavey, S. [1 ]
Barr, M. [1 ]
O'Byrne, K. [1 ]
Gately, K. [1 ]
机构：
[1] Trinity Coll Dublin, Dublin, Ireland
来源：
LUNG CANCER | 2012年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [1] The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines
    Heavey, Susan
    Barr, Martin
    Davies, Anthony
    O'Byrne, Ken
    Gately, Kathy
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [2] The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
    Mardanshahi, Alireza
    Gharibkandi, Nasrin Abbasi
    Vaseghi, Samaneh
    Abedi, Seyed Mohammad
    Molavipordanjani, Sajjad
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (08) : 6167 - 6180
  • [3] The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
    Alireza Mardanshahi
    Nasrin Abbasi Gharibkandi
    Samaneh Vaseghi
    Seyed Mohammad Abedi
    Sajjad Molavipordanjani
    Molecular Biology Reports, 2021, 48 : 1 - 14
  • [4] Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
    Lezzi, Alice
    Caiola, Elise
    Colombo, Marika
    Marabese, Mirko
    Broggini, Massimo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (12): : 4488 - +
  • [5] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [6] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [7] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [8] Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors
    Friedman, L.
    Belvin, M.
    Le Couter, J.
    Lin, K.
    Robillard, L.
    Sampath, D.
    Stern, H.
    Vijapurkar, U.
    Ye, W.
    Plowman, G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 71 - 71
  • [9] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [10] Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines
    Lim, Hui Jun
    Wang, Xiaochun
    Crowe, Philip
    Goldstein, David
    Yang, Jia-Lin
    ANTICANCER RESEARCH, 2016, 36 (11) : 5765 - 5771
12345